Nonclassical mechanisms to irreversibly suppress β-hematin crystal growth.


Journal

Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179

Informations de publication

Date de publication:
27 07 2023
Historique:
received: 05 10 2022
accepted: 14 06 2023
medline: 31 7 2023
pubmed: 28 7 2023
entrez: 27 7 2023
Statut: epublish

Résumé

Hematin crystallization is an essential element of heme detoxification of malaria parasites and its inhibition by antimalarial drugs is a common treatment avenue. We demonstrate at biomimetic conditions in vitro irreversible inhibition of hematin crystal growth due to distinct cooperative mechanisms that activate at high crystallization driving forces. The evolution of crystal shape after limited-time exposure to both artemisinin metabolites and quinoline-class antimalarials indicates that crystal growth remains suppressed after the artemisinin metabolites and the drugs are purged from the solution. Treating malaria parasites with the same agents reveals that three- and six-hour inhibitor pulses inhibit parasite growth with efficacy comparable to that of inhibitor exposure during the entire parasite lifetime. Time-resolved in situ atomic force microscopy (AFM), complemented by light scattering, reveals two molecular-level mechanisms of inhibitor action that prevent β-hematin growth recovery. Hematin adducts of artemisinins incite copious nucleation of nonextendable nanocrystals, which incorporate into larger growing crystals, whereas pyronaridine, a quinoline-class drug, promotes step bunches, which evolve to engender abundant dislocations. Both incorporated crystals and dislocations are known to induce lattice strain, which persists and permanently impedes crystal growth. Nucleation, step bunching, and other cooperative behaviors can be amplified or curtailed as means to control crystal sizes, size distributions, aspect ratios, and other properties essential for numerous fields that rely on crystalline materials.

Identifiants

pubmed: 37500754
doi: 10.1038/s42003-023-05046-z
pii: 10.1038/s42003-023-05046-z
pmc: PMC10374632
doi:

Substances chimiques

artemisinin 9RMU91N5K2
Hemin 743LRP9S7N
hemozoin 39404-00-7
Antimalarials 0
Quinolines 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S. Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

783

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI150763
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI138953
Pays : United States

Informations de copyright

© 2023. The Author(s).

Références

Antimicrob Agents Chemother. 1979 Dec;16(6):710-8
pubmed: 394674
PLoS One. 2012;7(2):e30949
pubmed: 22383983
Nature. 2020 Jan;577(7791):497-501
pubmed: 31942074
Int J Parasitol. 2002 Dec 4;32(13):1645-53
pubmed: 12435449
Nat Med. 2013 Feb;19(2):156-67
pubmed: 23389616
Cryst Growth Des. 2014 May 7;14(5):2123-2127
pubmed: 24839403
Acc Chem Res. 2021 Jun 1;54(11):2649-2659
pubmed: 33982570
Nat Mater. 2020 Oct;19(10):1074-1080
pubmed: 32778812
Science. 2003 Oct 10;302(5643):282-6
pubmed: 14551434
Biochemistry. 2018 Dec 26;57(51):6927-6934
pubmed: 30513202
Nature. 2000 Mar 16;404(6775):307-10
pubmed: 10749217
Nature. 2016 Aug 25;536(7617):446-50
pubmed: 27501150
Angew Chem Int Ed Engl. 2001 May 18;40(10):1954-1957
pubmed: 11385684
Proteins. 2001 Jun 1;43(4):343-52
pubmed: 11340651
Chem Rev. 2008 Nov;108(11):4899-914
pubmed: 19006402
Nature. 2021 Sep;597(7876):355-359
pubmed: 34526708
J Chem Phys. 2013 Sep 28;139(12):121911
pubmed: 24089723
J Biol Chem. 2021 Jan-Jun;296:100123
pubmed: 33239360
Sci Transl Med. 2019 Jan 2;11(473):
pubmed: 30602534
Biochemistry. 2018 Dec 26;57(51):6935-6945
pubmed: 30512926
Proc Natl Acad Sci U S A. 2017 Jul 18;114(29):7531-7536
pubmed: 28559329
Nature. 2001 Aug 23;412(6849):819-22
pubmed: 11518966
Nat Med. 2011 Oct 11;17(10):1217-20
pubmed: 21989013
J Biol Chem. 1998 Nov 20;273(47):31103-7
pubmed: 9813011
Biochemistry. 2006 Oct 17;45(41):12411-23
pubmed: 17029397
NPJ Microgravity. 2017 Aug 30;3:21
pubmed: 28868354
Phys Rev Lett. 2017 Nov 10;119(19):198101
pubmed: 29219496
Proc Natl Acad Sci U S A. 2015 Apr 21;112(16):4946-51
pubmed: 25831526
Sci Rep. 2017 Aug 8;7(1):7610
pubmed: 28790371
Phys Rev E Stat Nonlin Soft Matter Phys. 2015 Oct;92(4):042712
pubmed: 26565277
Nat Microbiol. 2017 Mar 13;2:17031
pubmed: 28288098
ChemMedChem. 2021 May 18;16(10):1515-1532
pubmed: 33523575
Proc Natl Acad Sci U S A. 2017 Jul 18;114(29):7483-7485
pubmed: 28696317
Nature. 2019 Oct;574(7778):394-398
pubmed: 31619792
Nat Rev Microbiol. 2009 Dec;7(12):864-74
pubmed: 19881520
J Parasitol. 1977 Oct;63(5):883-6
pubmed: 335035

Auteurs

Wenchuan Ma (W)

William A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, 77204, USA.

Victoria A Balta (VA)

W. Harry Feinstone Department of Molecular Microbiology and Immunology, Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA.

Weichun Pan (W)

William A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, 77204, USA.
Department of Applied Chemistry, Zhejiang Gongshang University, Hangzhou, Zhejiang, 314423, China.

Jeffrey D Rimer (JD)

William A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, 77204, USA. jrimer@central.uh.edu.
Department of Chemistry, University of Houston, Houston, TX, 77204, USA. jrimer@central.uh.edu.

David J Sullivan (DJ)

W. Harry Feinstone Department of Molecular Microbiology and Immunology, Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA. dsulliv7@jhmi.edu.

Peter G Vekilov (PG)

William A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, 77204, USA. vekilov@uh.edu.
Department of Chemistry, University of Houston, Houston, TX, 77204, USA. vekilov@uh.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH